+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genfit - logo

GENFIT is a biopharmaceutical company that focuses on developing diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. Its lead pipeline product elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis). Genfit SA was founded in 1999 and is headquartered in Loos, France.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2019 - Product Thumbnail Image

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 115 Pages
From
Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H2 2019 - Product Thumbnail Image

Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H2 2019

  • Drug Pipelines
  • August 2019
  • 106 Pages
From
2019 Cardiometabolic Disease Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 - Product Thumbnail Image

2019 Cardiometabolic Disease Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • Report
  • April 2019
  • 60 Pages
From
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2019 - Product Thumbnail Image

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H1 2019

  • Drug Pipelines
  • March 2019
  • 96 Pages
From
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018 - Product Thumbnail Image

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018

  • Drug Pipelines
  • July 2018
  • 106 Pages
From
Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2018 - Product Thumbnail Image

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2018

  • Drug Pipelines
  • July 2018
  • 83 Pages
From
Cardiometabolic Disease Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Cardiometabolic Disease Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • December 2018
  • 54 Pages
From
Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2022-2028 - Product Thumbnail Image

Global Non-alcoholic Steatohepatitis Biomarkers Market Forecast, 2022-2028

  • Report
  • August 2022
  • 130 Pages
From
Non-alcoholic Steatohepatitis Biomarkers Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Non-alcoholic Steatohepatitis Biomarkers Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2021
  • 114 Pages
From
PPAR-Beta / Delta Agonist - Pipeline Insight, 2022 - Product Thumbnail Image

PPAR-Beta / Delta Agonist - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
From
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Global Clinical Trials Review, H2, 2020 - Product Thumbnail Image

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Global Clinical Trials Review, H2, 2020

  • Clinical Trials
  • July 2020
  • 154 Pages
From
Biliary Cirrhosis Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Biliary Cirrhosis Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • November 2018
  • 142 Pages
From
Primary Biliary Cirrhosis Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Primary Biliary Cirrhosis Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • May 2018
  • 107 Pages
From
Genfit SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis - Product Thumbnail Image

Genfit SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

  • Company Profile
  • September 2022
  • 50 Pages
From
Loading Indicator